ABSTRACT
The COVID-19 pandemic is a kind of global disaster caused by the new coronavirus-19, the SARS-CoV-2 virus. Since the first eruption of this pandemic, which adversely affected the world in many ways, a large number of publications have been presented to the world of science. In this article, possible publication ethical dilemmas related to scientific articles increasing in number during the COVID-19 pandemic were tried to be reminded through two examples of articles.
Subject(s)
Betacoronavirus , Pandemics/ethics , Periodicals as Topic/ethics , Publication Bias , COVID-19 , Cardiovascular Diseases/drug therapy , Cardiovascular Diseases/mortality , Coronavirus Infections/drug therapy , Coronavirus Infections/mortality , Humans , Hydroxychloroquine/therapeutic use , Pneumonia, Viral/drug therapy , Pneumonia, Viral/mortality , SARS-CoV-2Subject(s)
Coronavirus Infections/drug therapy , Coronavirus/isolation & purification , Granulocyte Colony-Stimulating Factor/pharmacology , Granulocyte-Macrophage Colony-Stimulating Factor/pharmacology , Immune System/drug effects , Neoplasms/complications , Neoplasms/drug therapy , Pneumonia, Viral/drug therapy , Betacoronavirus , COVID-19 , Coronavirus Infections/epidemiology , Granulocytes , Humans , Neoplasms/immunology , Pandemics , Pneumonia, Viral/epidemiology , SARS-CoV-2ABSTRACT
As we know more about the clinical and laboratory features of COVID-19, which is now accepted as a pandemic, many questions have been raised about how to manage and monitor the treatment of cancer patients. It was determined that the incidence of lymphopenia increased in COVID-19 and there was a significant relationship between lymphopenia and mortality. This can be thought of as an unresponsive problem in how to maintain anti-cancer drugs that cause lymphopenia. This article was written for a hypothetical approach in cancer patients diagnosed with COVID-19 in order to be an idea of collecting data for treatment with anti-cancer drugs that cause lymphopenia.